Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Eli Lilly and Company have shared exciting news about their upcoming presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The company will be presenting data from studies of Verzenio, Retevmo, olomorasib, and imlunestrant during the event, along with an investor event to discuss their oncology strategy and pipeline.
Verzenio (abemaciclib) will be a focal point, with outcome data from a pivotal Phase 3 postMONARCH study being presented. This study evaluates Verzenio in combination with fulvestrant for patients with advanced breast cancer. In addition, Retevmo (selpercatinib) will share results from the Phase 1/2 LIBRETTO-121 study for pediatric and adolescent patients with solid tumors harboring a RET alteration.
Furthermore, olomorasib, an investigational KRAS G12C inhibitor, will be showcased in two oral presentations, demonstrating its efficacy in patients with advanced non-small cell lung cancer. Lastly, imlunestrant, an investigational oral SERD, will present data on its combination therapies for advanced breast cancer and endometrial cancer.
These presentations are highly anticipated and represent significant advancements in cancer treatment. Lilly’s commitment to innovative research and development continues to provide hope for patients worldwide. Stay tuned for more updates from the ASCO Annual Meeting.
For more information about these presentations and Lilly’s research, visit their website.
